In this article, we will look at the 11 Fastest Growing Penny Stocks to Buy Right Now.

Interest in smaller companies has been quietly building on Wall Street. After several years where mega-cap technology stocks dominated market returns, investors have started to look more closely at parts of the market that received far less attention. Many of these companies operate in niches that are growing quickly but remain underfollowed by large institutional investors. That dynamic often shows up most clearly in smaller and lower-priced stocks, where rapid revenue or earnings expansion can occur before the broader market fully notices.

Institutional investors have also started pointing to improving fundamentals in the small-cap universe. Franklin Templeton’s report entitled ‘What’s next for US small-caps in 2026?’, notes that “smaller companies generally fared better in terms of earnings growth,” and expects “accelerated earnings growth for small-cap stocks in 2026.” The firm adds that the environment could represent “an opportune time to invest in select small-caps for the long run.” AllianceBernstein has echoed a similar view, arguing that “the tide may be turning” for the segment. The firm highlights that “Small-Caps Benefit Disproportionally from Lower Rates”.

Taken together, these outlooks suggest that smaller companies with strong growth trajectories could begin attracting more investor attention, especially if earnings momentum continues to widen relative to larger peers. With that in mind, we take a closer look at the 11 Fastest Growing Penny Stocks to Buy Right Now.

Our Methodology

We used the Finviz screener to identify stocks that are trading below $5 per share. We further trimmed our list by focusing on companies that have achieved more than 50% sales growth over the past year and more than 50% growth over the past three years. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

11. Prairie Operating Co., LLC (NASDAQ:PROP)

On March 5, 2026, Prairie Operating Co., LLC (NASDAQ:PROP) reported the results of its independent year-end proved reserves evaluation for its oil and natural gas properties. The assessment was prepared by Cawley, Gillespie & Associates with an effective date of December 31, 2025, and was conducted under SEC guidelines, including Item 1202(a)(8) of Regulation S-K. Prairie reported total proved reserves of about 121 million barrels of oil equivalent, including 60 million barrels of oil, 195 billion cubic feet of natural gas, and 29 million barrels of natural gas liquids. Of the total, about 68 MMBoe were classified as proved developed reserves and 53 MMBoe as proved undeveloped. Operated and non-operated production at year-end 2025 was approximately 28,000 barrels of oil equivalent per day.

Using SEC pricing as of December 31, 2025 of $65.34 per barrel of oil and $3.387 per MMBtu of natural gas, and adjusting for transportation and other differentials, Prairie estimated net realized prices of $62.99 per barrel of oil, $0.797 per Mcf of natural gas, and $18.56 per barrel of natural gas liquids over the life of its proved properties. Estimated future net cash flows before federal income taxes tied to proved reserves totaled about $2.41 billion, with a discounted present value of roughly $1.22 billion using a 10% annual discount rate. About $860 million, or 71%, of that value is attributed to proved developed reserves.

On March 3, 2026, Prairie Operating announced leadership changes, including the voluntary resignation of CEO and Chairman Edward Kovalik and the retirement of President and Director Gary Hanna. The board appointed director Richard Frommer as Interim President and CEO while a search for a permanent chief executive is underway, and named Erik Thoresen as Chairman of the Board. The company said the search process will include both internal and external candidates.

Prairie Operating Co., LLC (NASDAQ:PROP) is an oil and gas production company focused on energy development.

10. Innoviz Technologies Ltd. (NASDAQ:INVZ)

On March 3, 2026, Innoviz Technologies Ltd. (NASDAQ:INVZ) announced a strategic collaboration with Dataspeed to distribute and integrate InnovizSMART LiDAR sensors into Dataspeed’s Drive-by-Wire vehicle systems across North America. Dataspeed develops drive-by-wire vehicle integration and autonomous research platforms used in defense, agriculture, mining, automotive, and off-highway industries. The platforms can be deployed in environments such as deserts, forests, open pit mines, farmland, and mountainous terrain, where sensors may be exposed to mud, dirt, condensation, and airborne debris. InnovizSMART is designed to address these challenges by maintaining performance despite optical blockages and delivering high-resolution, long-range 3D data to perception systems.

On February 25, 2026, Innoviz Technologies Ltd. (NASDAQ:INVZ) reported Q4 EPS of (10c) versus consensus of (8c) and revenue of $12.67M compared with consensus of $15M. CEO Omer Keilaf described 2025 as a “pivotal year,” citing more than doubled revenue, record gross margins, and expansion across multiple programs and end markets. Keilaf said the company is advancing Level 3 programs with the VW group and Mobileye and Level 4 programs with Daimler Truck, Mobileye, and VW. Innoviz has also introduced InnovizThree, designed for behind-the-windshield installations with a smaller form factor and lower power consumption. Outside automotive applications, the InnovizSMART platform is gaining traction in areas such as security, mobility, and intelligent transportation systems, while InnovizSMARTer integrates the company’s LiDAR with an Nvidia processor to deliver a one-box sensing solution.

Innoviz Technologies Ltd. (NASDAQ:INVZ) manufactures automotive-grade LiDAR sensors and perception software designed to support autonomous driving at scale.

9. TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating. William Plovanic said Q4 results came in line with the company’s preannouncement and that guidance was reiterated, with 2026 expected to be back-end loaded as the company doubles its sales force.

On March 5, 2026, TriSalus Life Sciences, Inc. (NASDAQ:TLSI) reported fourth-quarter EPS of (21c) versus consensus of (14c) and revenue of $13.205M compared with $8.261M in the prior year. CEO Mary Szela pointed to “strong commercial performance,” citing growing clinical adoption of the TriNav product suite and the company’s proprietary PEDD platform across multiple solid tumor indications. Szela added that TriSalus Life Sciences, Inc. (NASDAQ:TLSI) exceeded its 2025 revenue growth guidance as the company expanded the TriNav platform beyond liver indications.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) expects FY26 revenue of $60M to $62M compared with the consensus of $60.34M.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) develops drug delivery technology platforms and immuno-oncology therapeutics aimed at improving outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.

8. Geron Corporation (NASDAQ:GERN)

On February 25, 2026, Geron Corporation (NASDAQ:GERN) reported fourth-quarter EPS of (5c), compared with consensus estimates of (4c), and revenue of $48M versus consensus of $50.43M. CEO Harout Semerjian said strategic actions taken in the second half of 2025 were intended to position the company to drive RYTELO demand while lowering total operating expenses year over year. Semerjian highlighted the commercial opportunity for RYTELO in second-line lower-risk MDS, citing support from its FDA label, NCCN Guidelines, and expanding scientific evidence. The company also expects catalysts in the second half of 2026, including the IMpactMF interim analysis in relapsed or refractory myelofibrosis and initial data from real-world experience trials evaluating RYTELO in LR-MDS.

For fiscal year 2026, Geron Corporation (NASDAQ:GERN) expects Rytelo net product revenue of $220M to $240M and total operating expenses of $230M to $240M. The company said existing cash, cash equivalents, restricted cash, and marketable securities, together with anticipated U.S. sales of Rytelo, should be sufficient to fund operating requirements for the foreseeable future.

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing therapeutic products for oncology.

7. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

On March 5, 2026, H.C. Wainwright raised the price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $6 from $4 previously and maintained a Buy rating following the company’s fourth-quarter report. H.C. Wainwright increased the probability of success for pilavapadin to 30% from 15% and said the program could attract an “important partnership” as Lexicon’s clinical and regulatory progress helps de-risk the Phase 3-ready asset.

On March 5, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported fourth-quarter EPS of (4c) compared with consensus estimates of (7c). Revenue totaled $5.5 million versus the consensus of $3.14 million. As of December 31, 2025, the company held $125.2 million in cash, investments, and restricted cash, down from $238.0 million in cash and investments as of December 31, 2024. Chief Executive Officer Mike Exton said that the fourth quarter capped “an incredible year” for the company as it advanced pipeline programs, established development and commercialization agreements with global collaborators, and worked with regulators while maintaining operational efficiency. Mike Exton has added that the company entered 2026 with momentum and multiple upcoming catalysts.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat human disease.

6. EVgo, Inc. (NASDAQ:EVGO)

On March 6, 2026, UBS analyst Jon Windham lowered the price target on EVgo, Inc. (NASDAQ:EVGO) to $5.50 from $5.90 and maintained a Buy rating.

On March 4, 2026, Stifel analyst Stephen Gengaro lowered the price target on EVgo, Inc. (NASDAQ:EVGO) to $7 from $7.50 and kept a Buy rating after adjusting estimates following Q4 results. Stephen Gengaro said EVgo remains “the best pure-play EV charging company” and is well positioned for strong medium- to long-term growth. Also on March 4, RBC Capital lowered the price target on EVgo to $4.50 from $7 while maintaining an Outperform rating. RBC said the company’s 2026 outlook points to improving profitability, particularly in the second half of the year as stall deployments accelerate, though the guidance came in slightly below the firm’s forecast due to a slower deployment pace. RBC added that longer-term upside remains compelling but sentiment may stay muted in the near term given the macro backdrop.

On March 3, 2026, EVgo, Inc. (NASDAQ:EVGO) reported Q4 EPS of (4c) compared with (11c) last year and revenue of $118.5M versus consensus estimates of $102.61M. CEO Badar Khan said EVgo added more than 500 new charging stalls in Q4, bringing the year-end total to 5,100 stalls, while also delivering positive adjusted EBITDA for both the quarter and the full year 2025.

EVgo, Inc. (NASDAQ:EVGO) owns and operates a direct current fast charging network for electric vehicles in the United States.

5. Enovix Corporation (NASDAQ:ENVX)

On March 2, 2026, B. Riley lowered the price target on Enovix Corporation (NASDAQ:ENVX) to $10 from $17 previously and maintained a Buy rating.

On February 26, 2026, Canaccord lowered the price target on Enovix to $15 from $21 and kept a Buy rating, saying the firm remains convinced the company has the foundational technology needed for a potential paradigm shift in battery science. On the same day, Craig-Hallum lowered the price target on Enovix to $10 from $16 while maintaining a Buy rating. Craig-Hallum said Enovix could help drive the next generation of smartphone batteries but noted investors should watch the company’s volume production timeline as laser dicing issues are affecting yields, prompting the firm to reduce forward estimates while awaiting customer acceptance after testing.

On February 25, 2026, Enovix reported Q4 EPS of (14c) versus consensus estimates of (17c) and revenue of $11.3M compared with consensus of $10.25M. CEO Dr. Raj Talluri said the company’s top priority remains completing smartphone qualification and moving into commercial production, noting that evaluation samples met energy density, fast-charge, and safety requirements while cycle-life performance improved toward qualification targets. Enovix expects Q1 EPS of (14c) to (18c) compared with consensus of (15c).

Enovix Corporation (NASDAQ:ENVX) designs, develops, and manufactures lithium-ion battery cells for applications including wearables and IoT devices, smartphones, computing, electric vehicles, and other original equipment manufacturers.

4. Compugen Ltd. (NASDAQ:CGEN)

On March 2, 2026, Compugen Ltd. (NASDAQ:CGEN) reported fourth-quarter revenue of $67.3 million compared with $1.5 million in the prior year. Chief Executive Officer Eran Ophir said the company made important progress in 2025, citing the extension of its cash runway into 2029 through a non-dilutive monetization agreement with AstraZeneca for rilvegostomig. Ophir noted the agreement strengthens the company’s cash position while maintaining exposure to the potential long-term value of the asset, which AstraZeneca is advancing across 10 Phase 3 clinical trials in lung, gastrointestinal, and endometrial cancers, with additional Phase 1/2 data expected in 2026.

On February 12, 2026, Compugen Ltd. (NASDAQ:CGEN) announced the appointment of healthcare strategist Michele Holcomb as an independent director on its board. Holcomb brings more than 30 years of experience across biotechnology, pharmaceuticals, and healthcare services, including leadership roles at Cardinal Health, Teva, and McKinsey. The company said Holcomb’s background in strategy, business development, and partnerships is expected to support the use of its AI-driven discovery engine, pipeline development, and collaborations.

Compugen Ltd. (NASDAQ:CGEN) is a clinical-stage therapeutic discovery and development company focused on developing therapeutics and product candidates in Israel, the United States, and Europe.

3. SCYNEXIS, Inc. (NASDAQ:SCYX)

On February 26, 2026, SCYNEXIS, Inc. (NASDAQ:SCYX) announced that the first participants had been dosed in a Phase 1 single ascending dose and multiple ascending dose trial evaluating the intravenous formulation of its second-generation triterpenoid antifungal therapy, SCY-247. The therapy is being developed as a treatment for invasive candidiasis and as a prophylaxis therapy for invasive fungal disease, with results from the trial expected in 2026.

Earlier, SCYNEXIS, Inc. (NASDAQ:SCYX) said that the U.S. Food and Drug Administration granted Qualified Infectious Disease Product and Fast Track Designations for SCY-247. Further, SCYNEXIS, Inc. (NASDAQ:SCYX) said that it expects to initiate a Phase 1 study of the intravenous formulation and a Phase 2 study of the oral formulation in invasive candidiasis during 2026, and plans to release proof-of-concept data for the oral formulation the same year.

SCYNEXIS, Inc. (NASDAQ:SCYX) said it will also explore potential non-dilutive funding opportunities to support development of the program as antifungal resistance continues to emerge.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company focused on developing medicines to treat and prevent difficult-to-treat and drug-resistant infections.

2. Interactive Strength Inc. (NASDAQ:TRNR)

On March 4, 2026, Interactive Strength Inc. (NASDAQ:TRNR) announced that Sportstech Brands repaid its outstanding loan obligations and resolved the related legal proceedings. Under the settlement, Sportstech paid TRNR $6.4 million, representing full recovery of the $5.0 million loan principal plus interest and expense reimbursement, covering transaction costs and generating a return on the working capital loan. TRNR said it will withdraw its lawsuits and cancel the public auction of pledged Sportstech shares that had been scheduled for March 11, 2026. The settlement resolves all claims tied to the January 2025 and May 2025 loan agreements, including the Share Pledge Agreement covering 100% of Sportstech Brands Holding GmbH shares. TRNR confirmed the $6.4 million payment has already been received and said it now has no ownership interest in or involvement with Sportstech.

On February 18, 2026, Interactive Strength Inc. (NASDAQ:TRNR) signed a definitive agreement to acquire Ergatta after previously announcing a letter of intent on January 9. The company described Ergatta as a Brooklyn-based connected fitness company focused on game-based fitness content with monthly net retention above 98%. Ergatta is expected to generate more than $10 million in 2026 revenue, with about 70% from recurring subscriptions and an EBITDA margin of roughly 30%. TRNR said the maximum enterprise value of the deal could reach $19.5 million, assuming full earn-out targets are achieved. The base transaction value of $8.8 million includes $1.8 million in cash at closing, $1.8 million in debt, and $5.3 million in equity locked up until May 2027. Additional consideration of up to $9.8 million may be paid if Ergatta reaches about $4 million in 2026 EBITDA, with up to another $1 million tied to 2027 EBITDA targets. The company expects the acquisition to close in Q1 2026.

Interactive Strength Inc. (NASDAQ:TRNR) develops and sells specialty fitness equipment and virtual training solutions for commercial and at-home markets in the United States, Europe, and Asia.

1. Opus Genetics, Inc. (NASDAQ:IRD)

On March 2, 2026, BTIG raised the price target on Opus Genetics, Inc. (NASDAQ:IRD) to $12 from $7 and maintained a Buy rating. BTIG said the company’s investment story appears to be gaining momentum after the initial BEST1 correction patient exceeded expectations, with the highly visually impaired “sentinel patient” showing both the structural changes anticipated and signs of improved vision.

On February 27, 2026, Opus Genetics presented new clinical data from its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy at the 49th Annual Meeting of the Macula Society in San Diego. Three-month results from the first adult participant showed the therapy was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities following subretinal administration. The sentinel participant, a 63-year-old female with Autosomal-Recessive Bestrophinopathy and severe functional impairment, showed early signals of functional vision improvement, including a 12-letter gain in Best Corrected Visual Acuity in the treated eye. Structural improvements were also observed, including a 23% decrease in central subfield thickness and resolution of intraretinal fluid in some areas.

On February 25, 2026, Opus Genetics said the U.S. FDA accepted for review the supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia, assigning a PDUFA goal date of October 17, 2026. Recruitment in the Phase 1/2 OPGx-BEST1 study is ongoing at two U.S. clinical sites, with additional locations expected to open in Florida, Cincinnati, and New York.

Opus Genetics, Inc. (NASDAQ:IRD) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for inherited retinal diseases.

While we acknowledge the potential of IRD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.